This Million Targets Drug: A $7M Bet on a CNS Breakthrough
A focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
This intro covers zero-fee index funds available in 2024, helping you compare costs and identify cost-efficient options for long-term investing.
15,531 articlesA focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
A new ETF aims to monetize the price swings of Rocket Lab and other space names by selling weekly put spreads to fund...
Red Cat Holdings faced a sharp one-day re-pricing after mixed quarterly results, underscoring how revenue beats can c...
If you’re targeting 2030 for your retirement, timing your Social Security claim could be the biggest financial move y...
Oil shocks aren’t just headlines. This guide breaks down five real ways a $100 oil price affects your wallet and your...
A short-seller report rattled SoFi stock, but headlines don’t always tell the full story. This analysis digs into the...
An unauthorized mint triggered a depeg for Resolv’s stablecoin, with an attacker minting 80 million unbacked tokens a...
Bitcoin dipped over the weekend, but traders rotated into infrastructure-focused bets as the Bitcoin Hyper presale su...
Inflation cools and growth slows, reviving worries about stagflation. Analysts say america being haunted 1970s could ...
When a juggernaut like Fortnite cools its engagement, the ripple effect hits the entire company. This piece digs into...
BlackRock's Larry Fink presents two stark paths for oil and markets tied to the Iran conflict, challenging households...
The passing of a long-time CEO marks a watershed moment for any company. This guide helps investors evaluate Simon Pr...